BIOSANTE PHARMACEUTICALS TO PRESENT POSITIVE STUDY RESULTS FOR POTENTIAL ADJUVANTED BIRD FLU VACCINE
BioSante Pharmaceuticals, Inc. today announced that it will present positive
results of several pre-clinical studies, demonstrating that its calcium phosphate
(CaP) nanoparticle-based vaccine adjuvant, BioVant, may serve as an adjuvant
for the development of an effective flu virus vaccine, including the potentially
pandemic H5N1 bird flu.
Genetic Engineering News